The SARS-CoV-2 coronavirus that emerged late 2019 and disseminated worldwide leading to the COVID-19 pandemic had a huge impact on the healthcare system and on our lives. In the countries were epidemic has a decreasing trend, the epidemiological surveillance is of paramount importance to prevent a new increase of COVID-19 cases.
Numerous serological assays have been developed and are available, but these tests focus on the detection of antibodies directed towards one single antigen. While the most sensitive tests target antibodies against the nucleocapsid protein (NP), the antibodies against the receptor binding domain (RBD) of the spike protein are expected to confer protection by inhibiting the virus entry into the host cell.
The COVID-19 Sero NP/RBD test is a serological assay that allows to detect and differentiate antibodies against NP and RBD in a single assay within 15 minutes only.